When will Canafenib be available in China and how much does it cost per box?

Encorafenib (Encorafenib), also known as encorafenib, is an oral small molecule BRAF kinase inhibitor developed by Array BioPharma, a subsidiary of Pfizer. This drug can specifically inhibit the growth of tumor cell lines expressing BRAF V600E, V600D and V600K mutations, thereby exerting anti-tumor effects.

Canafenib was first approved by the U.S. Food and Drug Administration (FDA) in June 2018. It is mainly used to treat unresectable or metastatic tumors with specific BRAF gene mutations, especially melanoma and colorectal cancer patients with BRAF V600E or V600K mutation-positive tumors. In clinical trials, the combination of canafenib and binimetinib achieved significant therapeutic effects in the treatment of patients with BRAF-mutant melanoma, significantly extending the patient's progression-free survival.

However, it should be noted that canafenib has not yet received marketing approval in China. Nonetheless, with the continuous advancement of global medical technology and the strengthening of cross-border cooperation, domestic patients are expected to obtain treatment opportunities with this innovative drug through legal channels in the future.

In addition, the use of canafenib needs to be carried out under the guidance of professional doctors to ensure that patients can receive treatment safely and effectively. BecauseBRAF inhibitors may increase the risk of proliferation of certain types of tumor cells, detailed genetic testing and disease assessment are required before use. At the same time, patients also need to closely monitor their physical condition during use, and promptly detect and deal with possible adverse reactions.

Currently, canafenib is not yet on the market in China, so domestic patients cannot directly obtain this drug for the time being. It is reported that the drug has been launched in Europe, with the price of 75mg and 42 pills being about 17,000 yuan, and the price of 75mg and 168 pills being about 59,000 yuan. If a patient needs canafenib, please consult a regular overseas medical consultation service organization.

To sum up, canafenib is a drug that targets specific Although effective therapeutic drugs for tumors with BRAF gene mutations are not yet on the market in China, their therapeutic efficacy and safety have been widely recognized. With the continuous advancement of medical technology, domestic patients are expected to have more innovative drug treatment options in the future.